Source
HLTH
Viz.ai has announced a partnership with Alnylam Pharmaceuticals to improve early identification and care coordination for patients with cardiac amyloidosis, a progressive and frequently underdiagnosed cause of heart failure. The collaboration focuses on deploying an AI-enabled care pathway designed to identify patients earlier and guide clinicians through standardized diagnostic and treatment processes.
News Url